[Form 4] Disc Medicine, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) reported an insider transaction by its Chief Operating Officer on 11/11/2025. The officer exercised a stock option for 30,000 shares at $2.65 and executed pre‑planned sales under a Rule 10b5‑1 trading plan adopted on July 22, 2025.

The sales occurred in four tranches: 8,015 shares at a weighted average price of $83.1453, 4,585 shares at $83.9877, 9,360 shares at $85.3301, and 8,040 shares at $85.9129. Following these transactions, the officer beneficially owned 40,555 shares directly. The option carried an exercise price of $2.65 and is shown as fully vested, with an expiration of 08/10/2030; 7,941 derivative securities remained beneficially owned after the transactions.

Insights

Insider transactions analyst

Routine, pre‑planned insider trades with clear disclosures.

The COO exercised options at $2.65 for 30,000 shares and sold shares the same day in four blocks at weighted average prices between $83.1453 and $85.9129. The filing cites a Rule 10b5‑1 plan adopted on July 22, 2025, indicating the trades were pre‑scheduled.

Post‑trade, direct beneficial ownership is 40,555 shares, and 7,941 derivative securities remain. The option was fully vested and expires on 08/10/2030. This is administrative disclosure and does not, by itself, indicate a change in business outlook.

Actual market impact depends on broader trading volumes and investor interpretation of insider activity; the filing lists prices and amounts but provides no guidance or strategic context.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jonathan Yen-Wen

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		M(1)		30,000	A	$2.65	70,555	D
Common Stock	11/11/2025		S(1)		8,015	D	$83.1453(2)	62,540	D
Common Stock	11/11/2025		S(1)		4,585	D	$83.9877(3)	57,955	D
Common Stock	11/11/2025		S(1)		9,360	D	$85.3301(4)	48,595	D
Common Stock	11/11/2025		S(1)		8,040	D	$85.9129(5)	40,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.65	11/11/2025		M(1)			30,000	(6)	08/10/2030	Common Stock	30,000	$0	7,941	D

Explanation of Responses:

1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 22, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.63 to $83.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.63 to $84.62, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.69 to $85.68, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.69 to $86.28, inclusive.

6. The shares underlying this option are fully vested and exercisable as of the date hereof.

	By: /s/ Rahul Khara, as Attorney-in-Fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRON disclose?

The COO exercised a stock option for 30,000 shares at $2.65 and sold shares in four transactions on 11/11/2025 under a Rule 10b5-1 plan.

What prices were the IRON shares sold at by the COO?

Weighted average prices were $83.1453, $83.9877, $85.3301, and $85.9129, each reflecting multiple trades within stated ranges.

How many IRON shares does the reporting person own after the trades?

The officer beneficially owned 40,555 shares directly after the reported transactions.

Was the sale pre-arranged under a 10b5-1 plan for IRON?

Yes. The trades were effected under a Rule 10b5‑1 trading plan adopted on July 22, 2025.

What are the details of the exercised stock option for IRON?

It covered 30,000 shares at an exercise price of $2.65, was fully vested, and has an expiration date of 08/10/2030.

How many derivative securities remain after the transactions?

The filing shows 7,941 derivative securities beneficially owned following the transactions.